ArticleTravel medicine and infectious disease
Coronavirus infections reported by ProMED, February 2000-January 2020.
Article in Travel medicine and infectious disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Role of digital technology in epidemic control: a scoping review on COVID-19 and Ebola.BMJ open · 2025Article
- What makes an epidemic a disaster: the future of epidemics within the EM-DAT International Disaster Database.BMC public health · 2025Article
- Digital surveillance in Latin American diseases outbreaks: information extraction from a novel Spanish corpus.BMC bioinformatics · 2022Article
- Insect cell expression and purification of recombinant SARS-COV-2 spike proteins that demonstrate ACE2 binding.Protein science : a publication of the Protein Society · 2022Article
- SARS-CoV-2 nsp5 Exhibits Stronger Catalytic Activity and Interferon Antagonism than Its SARS-CoV Ortholog.Journal of virology · 2022Article
- Silver Nanoparticles as Potential Antiviral Agents.Pharmaceutics · 2021Review
- Silver nanoparticles as a potential treatment against SARS-CoV-2: A review.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2021Review
- A Multidisciplinary Approach to Coronavirus Disease (COVID-19).Molecules (Basel, Switzerland) · 2021Review
- An extended fuzzy decision-making framework using hesitant fuzzy sets for the drug selection to treat the mild symptoms of Coronavirus Disease 2019 (COVID-19).Applied soft computing · 2021Article
- Exploring geographical distribution of transportation research themes related to COVID-19 using text network approach.Sustainable cities and society · 2021Article
- A district-level susceptibility and vulnerability assessment of the COVID-19 pandemic's footprint in India.Spatial and spatio-temporal epidemiology · 2021Article
- Study Protocol for a Global Survey: Awareness and Preparedness of Hospital Staff Against Coronavirus Disease (COVID-19) Outbreak.Frontiers in public health · 2021Article
- Article
- Bats in ecosystems and their Wide spectrum of viral infectious potential threats: SARS-CoV-2 and other emerging viruses.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Review
- "What If We Get Sick?": Spanish Adaptation and Validation of the Fear of Illness and Virus Evaluation Scale in a Non-clinical Sample Exposed to the COVID-19 Pandemic.Frontiers in psychology · 2021Article
- Medical negligence in healthcare organizations and its impact on patient safety and public health: a bibliometric study.F1000Research · 2021Article
- A model for the effective COVID-19 identification in uncertainty environment using primary symptoms and CT scans.Health informatics journal · 2020Article
- Coronavirus Disease 2019-COVID-19.Clinical microbiology reviews · 2020Review
- Virology, pathogenesis, diagnosis and in-line treatment of COVID-19.European journal of pharmacology · 2020Review
- SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic.Annals of clinical microbiology and antimicrobials · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSources describing the global burden of emerging diseases accurately are still limited. We reviewed coronavirus infections reported by ProMED and assessed the reliability of the data retrieved compared to published reports. We evaluated the effectiveness of ProMED as a source of epidemiological data on coronavirus.
methodsUsing the keyword "coronavirus" in the ProMED search engine, we reviewed all the information from the reports and collected data using a structured form, including year, country, gender, occupation, the number of infected individuals, and the number of fatal cases.
resultsWe identified 109 entries reported between February 29, 2000 and January 22, 2020. A total of 966 cases were reported, with death reported in 188 cases, suggesting an overall case fatality rate (CFR) of 19.5%. Of 70 cases for which the gender was reported, 47 (67.1%) were male. Most of the cases were reported from China, the United Arab Emirates, and Saudi Arabia, with reports from other countries, including imported cases in Europe and North America.
conclusionsInternet-based reporting systems such as ProMED are useful to gather information and synthesize knowledge on emerging infections. Although certain areas need to be improved, ProMED provided useful information about coronaviruses especially during outbreaks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.